Neurosearch A/s

Cadent Therapeutics, Inc.

Aniona Aps

Universitá Degli Studi Di Siena

Karin Sandager Nielsen

Dan Peters

Tina Holm Johansen

Lene Teuber

Palle Christophersen

Gregg F Keaney

Martin R Jefson

Janus Schreiber Larsen

Ulrik Svane Sørensen

Dorte Strøbæk

Thomas Amos Jacobsen

Dipak Vasantrao Amrutkar

Kelly Foster

Gordon Munro

Elsebet Østergaard Nielsen

Alex Haahr Gouliaev

Elsebet Ostergaard Nielsen

Jorgen Scheel-Kruger

Thomas Varming

Claus Mathiesen

Lars Christian B Rønn

Morgens Larsen

Barbara Hartz

Stefania Butini

Jørgen Scheel-Krüger

Caterina Fattorusso

Elsebet ØStergaard Nielsen

Giuseppe Campiani

Silvia Franceschini

Zia Irene Thale

Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.

Potassium channel modulators

Provided herein are compounds of the formula: or pharmaceutically acceptable salts thereof, and compositions comprising such compounds for use in the treatment of diseases or conditions responsive to modulation of the small conductance calcium-activated potassium channel (SK channel).

The present application discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the application discloses the use of these compounds, a method for therapy and to pharmaceutical compositions comprising these compounds.

Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

The present applications discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. In other aspects the applications discloses the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. 

This invention relates to novel 2-(phenylamino)benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels

This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels

This invention relates to novel benzothiazine derivatives of Formula I useful as modulators of the AMPA sensitive glutamate receptors, pharmaceutical compositions comprising such compounds and their use in therapy.

Benzothiazine derivatives, their preparation and use

This invention relates to the use of the combined action of a compound with neurotrophic activity and an adenosine Areceptor antagonist for the treatment of Parkinson's disease.

[object Object]

Growing community of inventors

Fredensborg, Denmark

Karin Sandager Nielsen